

Fiducial Markers Market by Product (Metal Based Markers (Gold, Gold Combination) Polymer Markers), Cancer Type (Prostate, Lung, Breast), Modality (CT, CBCT, MRI, Ultrasound), End user (Hospitals, Outpatient Facilities) - Global Forecast to 2025

<https://marketpublishers.com/r/F4E7A6A56F8AEN.html>

Date: February 2020

Pages: 147

Price: US\$ 5,650.00 (Single User License)

ID: F4E7A6A56F8AEN

Abstracts

“The fiducial markers market is projected to grow at a CAGR of 4.5% from 2019 to 2025.”

The global fiducial markers market is valued at USD 95 million in 2019 and expected to reach USD 123 million by 2025, at a CAGR of 4.5% from 2019 to 2025. The growth of the fiducial markers market is mainly attributed to factors such as the growing incidences of cancer, growing adoption of radiotherapy procedures, improving reimbursement scenario, and rising awareness on radiotherapy. These factors have prompted market players to improve and strengthen their current manufacturing and distribution capabilities—especially in emerging markets, which are expected to witness the highest growth. However, a dearth of skilled professionals, high marker costs, and a lack of adequate healthcare infrastructure are expected to limit market growth during the forecast period.

“The metal-based markers segment commanded the largest share of the fiducial markers market in 2018.”

Based on the product, the fiducial markers market is segmented into metal-based, polymer-based, and other fiducial markers. The metal-based markers segment is further subsegmented into pure gold markers, gold combination markers, and other metal-based markers (tungsten, platinum, and nitinol, among others). The metal-based markers segment commanded the largest share of the fiducial markers market in 2018.

The growing adoption of IGRT for the treatment of prostate cancer and the rising incidences of prostate cancer are expected to fuel the adoption of metal-based fiducial markers in the near future.

“The CT/CBCT segment held the major share of the global market in 2018.”

In terms of modality, the fiducial markers market is classified into CT/CBCT, MRI, ultrasound, and radiotherapy. The CT/CBCT segment held the major share of the global market in 2018. It is anticipated to reach USD 54.0 million by 2025. CBCT is preferred for prostate and lung cancer indications, as it can effectively detect changes in the position of cancer tumors. This is supporting the growth of the CT/CBCT segment.

“North America is projected to hold the largest share of the market.”

The fiducial markers market, by region, is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. North America is projected to hold the largest share of the market, by region, during the forecast period. This is attributed to the expansion of the target patient population, favorable reimbursement scenario, greater accessibility to radiotherapy procedures, and the presence of major players in this region.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1–45%, Tier 2–34%, and Tier 3– 21%

By Designation: C-level–47%, Director-level–33%, and Others–20%

By Region: North America–35%, Europe–32%, Asia Pacific–25%, Latin America–6%, and the Middle East & Africa–2%

In 2018, the global fiducial markers market was dominated by CIVCO Radiotherapy (US), IZI Medical Products (US), Boston Scientific Corporation (US), Naslund Medical AB (Sweden), and IBA (Belgium).

Research Coverage:

The report analyzes the market for various fiducial markers and their adoption patterns. It aims at estimating the market size and future growth potential of the fiducial markers

market and its subsegments. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios offered by top players in the fiducial markers market

Product Development/Innovation: Detailed insights on upcoming trends, R&D activities, and product launches in the fiducial markers market

Market Development: Comprehensive information on lucrative emerging regions

Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the fiducial markers market

Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of leading market players.

Contents

1 INTRODUCTION

- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
 - 1.2.1 MARKETS COVERED
 - 1.2.2 YEARS CONSIDERED FOR THE STUDY
- 1.3 CURRENCY
- 1.4 LIMITATIONS
- 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 Key data from secondary sources
 - 2.1.2 PRIMARY DATA
 - 2.1.2.1 Breakdown of primaries
 - 2.1.2.2 Key data from primary sources
- 2.2 MARKET SIZE ESTIMATION
 - 2.2.1 PRODUCT-BASED MARKET ESTIMATION
 - 2.2.2 END USER-BASED MARKET SIZE ESTIMATION
 - 2.2.3 PRIMARY RESEARCH VALIDATION
- 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
- 2.4 ASSUMPTIONS FOR THE STUDY
- 2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 FIDUCIAL MARKERS: MARKET OVERVIEW
- 4.2 FIDUCIAL MARKERS MARKET, BY PRODUCT & REGION, 2019
- 4.3 FIDUCIAL MARKERS MARKET, BY MODALITY, 2019–2025
- 4.4 FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2019 VS. 2025
- 4.5 FIDUCIAL MARKERS MARKET SHARE, BY END USER, 2019 VS. 2025
- 4.6 GEOGRAPHIC SNAPSHOT OF THE FIDUCIAL MARKERS MARKET, 2019

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

- 5.2.1.1 Growing incidence of cancer
- 5.2.1.2 Improving reimbursement scenario
- 5.2.1.3 Rising awareness on radiotherapy
- 5.2.1.4 Rising investments and funding for cancer research

5.2.2 RESTRAINTS

- 5.2.2.1 Lack of adequate healthcare infrastructure and premium pricing of modalities
- 5.2.2.2 Alternative therapies and high marker costs

5.2.3 OPPORTUNITIES

- 5.2.3.1 Emerging economies

5.2.4 CHALLENGES

- 5.2.4.1 Complications associated with the placement of fiducial markers
- 5.2.4.2 Shortage of trained personnel

6 FIDUCIAL MARKERS MARKET, BY PRODUCT

6.1 INTRODUCTION

6.2 METAL-BASED MARKERS

6.2.1 PURE GOLD MARKERS

6.2.1.1 Pure gold markers hold the largest share of the metal-based fiducial markers market

6.2.2 GOLD COMBINATION MARKERS

6.2.2.1 High-precision advantages and versatility are driving demand for gold combination markers

6.2.3 OTHER METAL-BASED MARKERS

6.3 POLYMER-BASED MARKERS

6.3.1 VISIBILITY LIMITATIONS HAVE AFFECTED DEMAND FOR POLYMER-BASED MARKERS

6.4 OTHER FIDUCIAL MARKERS

7 FIDUCIAL MARKERS MARKET, BY MODALITY

7.1 INTRODUCTION

7.2 CT/CBCT

7.2.1 TECHNOLOGICAL ADVANCEMENTS AND RISING ADOPTION OF CBCT ARE

EXPECTED TO FUEL MARKET GROWTH

7.3 ULTRASOUND

7.3.1 RISING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES IS DRIVING DEMAND FOR ULTRASOUND

7.4 MRI

7.4.1 HIGH ADOPTION OF COMBINED CT-MRI MODALITIES FOR FM LOCALIZATION WILL DRIVE SEGMENTAL GROWTH

7.5 RADIOTHERAPY

7.5.1 HIGH SUCCESS RATE OF SBRT USING RADIOTHERAPY SYSTEMS WILL DRIVE THE SEGMENT GROWTH

8 FIDUCIAL MARKERS MARKET, BY CANCER TYPE

8.1 INTRODUCTION

8.2 PROSTATE CANCER

8.2.1 PROSTATE CANCER HOLDS THE LARGEST SHARE OF THE MARKET, BY CANCER TYPE

8.3 LUNG CANCER

8.3.1 TECHNOLOGICAL ADVANCEMENTS AND PRODUCT APPROVALS WILL DRIVE MARKET GROWTH

8.4 GASTRIC CANCER

8.4.1 HIGH INCIDENCE OF GASTRIC CANCER AND ADVANCEMENTS IN TREATMENT SUPPORT MARKET GROWTH

8.5 BREAST CANCER

8.5.1 EFFICACY OF ADVANCED RADIOLOGY TREATMENT FOR BREAST CANCER WILL ENSURE THE GROWTH OF THE MARKET

8.6 OTHER CANCERS

9 FIDUCIAL MARKERS MARKET, BY END USER

9.1 INTRODUCTION

9.2 HOSPITALS & OUTPATIENT FACILITIES

9.2.1 HOSPITALS & OUTPATIENT FACILITIES HOLD THE LARGEST SHARE OF THE MARKET

9.3 INDEPENDENT RADIOTHERAPY CENTERS

9.3.1 UNFAVORABLE REIMBURSEMENT SCENARIO WILL HAMPER GROWTH

9.4 CANCER RESEARCH CENTERS

9.4.1 RISING INVESTMENTS AND FUNDING WILL INCREASE RESEARCH ACTIVITIES AND SUPPORT MARKET GROWTH

10 FIDUCIAL MARKERS MARKET, BY REGION

10.1 INTRODUCTION

10.2 NORTH AMERICA

10.2.1 US

10.2.1.1 US commanded the largest share of the market in 2018

10.2.2 CANADA

10.2.2.1 Public-private initiatives are expected to support the adoption of radiotherapy procedures and fiducial markers

10.3 EUROPE

10.3.1 GERMANY

10.3.1.1 Favorable reimbursement scenario for radiotherapy is supporting market growth in Germany

10.3.2 UK

10.3.2.1 Rising cancer incidence and the presence of highly developed healthcare infrastructure are supporting market growth in the UK

10.3.3 FRANCE

10.3.3.1 Increasing access to radiotherapy will drive market growth

10.3.4 SPAIN

10.3.4.1 Shortage of human resources and lack of accessibility may hinder market growth

10.3.5 ITALY

10.3.5.1 Rising research activities will support market growth

10.3.6 REST OF EUROPE

10.4 ASIA PACIFIC

10.4.1 JAPAN

10.4.1.1 Japan dominates the APAC fiducial markers market

10.4.2 CHINA

10.4.2.1 China will register the highest growth in the APAC fiducial markers market due to the growing target patient population

10.4.3 INDIA

10.4.3.1 Indian market is expected to be driven by the surge in patient population and favorable government initiatives

10.4.4 SOUTH KOREA

10.4.4.1 Growing adoption of advanced EBRT is contributing to market growth in the country

10.4.5 AUSTRALIA

10.4.5.1 Favorable reimbursement scenario will support market growth

10.4.6 REST OF APAC

10.5 LATIN AMERICA

10.5.1 BRAZIL

10.5.1.1 Brazil held the largest share of the Latin American fiducial markers market in 2018

10.5.2 MEXICO

10.5.2.1 Initiatives are being undertaken to spread awareness and boost access to radiotherapy

10.5.3 REST OF LATAM

10.6 MIDDLE EAST & AFRICA

10.6.1 POOR HEALTHCARE INFRASTRUCTURE AND REIMBURSEMENT SCENARIO RESTRAIN MARKET GROWTH

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW

11.2 MARKET SHARE ANALYSIS

11.3 COMPETITIVE SCENARIO

11.3.1 KEY PRODUCT LAUNCHES AND ENHANCEMENTS

11.3.2 KEY AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS

11.3.3 KEY ACQUISITIONS

11.3.4 KEY EXPANSIONS

11.4 COMPETITIVE LEADERSHIP MAPPING

11.4.1 VISIONARY LEADERS

11.4.2 INNOVATORS

11.4.3 DYNAMIC DIFFERENTIATORS

11.4.4 EMERGING COMPANIES

12 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View)*

12.1 CIVCO RADIOTHERAPY

12.2 BOSTON SCIENTIFIC CORPORATION

12.3 IZI MEDICAL PRODUCTS

12.4 IBA

12.5 NASLUND MEDICAL AB

12.6 MEDTRONIC

12.7 BEST MEDICAL INTERNATIONAL, INC.

12.8 NANOVI A/S

- 12.9 CARBON MEDICAL TECHNOLOGIES
- 12.10 ECKERT & ZIEGLER
- 12.11 INNOVATIVE ONCOLOGY SOLUTIONS
- 12.12 QLRAD INC.
- 12.13 STELLAR MEDICAL
- 12.14 JJ-MEDTECH
- 12.15 QFIX
- 12.16 OTHER COMPANIES
 - 12.16.1 VARIAN MEDICAL SYSTEMS, INC.
 - 12.16.2 BEEKLEY CORPORATION
 - 12.16.3 INNOMEDICUS AG
 - 12.16.4 MEDITRONIX CORPORATION
 - 12.16.5 SEEDOS LTD

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

- 13.1 DISCUSSION GUIDE
- 13.2 KNOWLEDGE STORE: MARKETSSANDMARKETS' SUBSCRIPTION PORTAL
- 13.3 AVAILABLE CUSTOMIZATIONS
- 13.4 RELATED REPORTS
- 13.5 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 NATIONAL AVERAGE MEDICARE REIMBURSEMENT: OUTPATIENT PROSPECTIVE PAYMENT SYSTEM (OPPS) ESTIMATED PER COURSE

TABLE 2 REIMBURSEMENT FOR IMRT IN GERMANY, 2017

TABLE 3 FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 4 METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 5 METAL-BASED FIDUCIAL MARKERS MARKET, BY REGION, 2017–2025 (USD MILLION)

TABLE 6 METAL-BASED FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION)

TABLE 7 METAL-BASED FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2017–2025 (USD MILLION)

TABLE 8 METAL-BASED FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION)

TABLE 9 PURE GOLD FIDUCIAL MARKERS MARKET, BY REGION, 2017–2025 (USD MILLION)

TABLE 10 PURE GOLD FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION)

TABLE 11 PURE GOLD FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2017–2025 (USD MILLION)

TABLE 12 PURE GOLD FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION)

TABLE 13 GOLD COMBINATION FIDUCIAL MARKERS MARKET, BY REGION, 2017–2025 (USD MILLION)

TABLE 14 GOLD COMBINATION FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION)

TABLE 15 GOLD COMBINATION FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2017–2025 (USD MILLION)

TABLE 16 GOLD COMBINATION FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION)

TABLE 17 OTHER METAL-BASED FIDUCIAL MARKERS MARKET, BY REGION, 2017–2025 (USD MILLION)

TABLE 18 OTHER METAL-BASED FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION)

TABLE 19 OTHER METAL-BASED FIDUCIAL MARKERS MARKET, BY CANCER

TYPE, 2017–2025 (USD MILLION)

TABLE 20 OTHER METAL-BASED FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION)

TABLE 21 POLYMER-BASED FIDUCIAL MARKERS MARKET, BY REGION, 2017–2025 (USD MILLION)

TABLE 22 POLYMER-BASED FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION)

TABLE 23 POLYMER-BASED FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2017–2025 (USD MILLION)

TABLE 24 POLYMER-BASED FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION)

TABLE 25 OTHER FIDUCIAL MARKERS MARKET, BY REGION, 2017–2025 (USD MILLION)

TABLE 26 OTHER FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION)

TABLE 27 OTHER FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2017–2025 (USD MILLION)

TABLE 28 OTHER FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION)

TABLE 29 FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION)

TABLE 30 FIDUCIAL MARKERS MARKET FOR CT/CBCT, BY REGION, 2017–2025 (USD MILLION)

TABLE 31 FIDUCIAL MARKERS MARKET FOR ULTRASOUND, BY REGION, 2017–2025 (USD MILLION)

TABLE 32 FIDUCIAL MARKERS MARKET FOR CANCER RESEARCH CENTERS, BY REGION, 2017–2025 (USD MILLION)

TABLE 33 CONVENTIONAL EBRT VS SBRT

TABLE 34 FIDUCIAL MARKERS MARKET FOR RADIOTHERAPY, BY REGION, 2017–2025 (USD MILLION)

TABLE 35 FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2017–2025 (USD MILLION)

TABLE 36 NEWLY DIAGNOSED PROSTATE CANCER CASES, BY KEY COUNTRY, 2018

TABLE 37 FIDUCIAL MARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2017–2025 (USD MILLION)

TABLE 38 FIDUCIAL MARKERS MARKET FOR LUNG CANCER, BY REGION, 2017–2025 (USD MILLION)

TABLE 39 NEW GASTRIC CANCER CASES DIAGNOSED, BY COUNTRY, 2018

TABLE 40 FIDUCIAL MARKERS MARKET FOR GASTRIC CANCER, BY REGION, 2017–2025 (USD MILLION)

TABLE 41 NEW BREAST CANCER CASES DIAGNOSED, BY COUNTRY, 2018

TABLE 42 FIDUCIAL MARKERS MARKET FOR BREAST CANCER, BY REGION, 2017–2025 (USD MILLION)

TABLE 43 FIDUCIAL MARKERS MARKET FOR OTHER CANCERS, BY REGION, 2017–2025 (USD MILLION)

TABLE 44 FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION)

TABLE 45 FIDUCIAL MARKERS MARKET FOR HOSPITALS & OUTPATIENT FACILITIES, BY REGION, 2017–2025 (USD MILLION)

TABLE 46 FIDUCIAL MARKERS MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2017–2025 (USD MILLION)

TABLE 47 FIDUCIAL MARKERS MARKET FOR CANCER RESEARCH CENTERS, BY REGION, 2017–2025 (USD MILLION)

TABLE 48 FIDUCIAL MARKERS MARKET, BY REGION, 2017–2025 (USD MILLION)

TABLE 49 NORTH AMERICA: FIDUCIAL MARKERS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)

TABLE 50 NORTH AMERICA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 51 NORTH AMERICA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 52 NORTH AMERICA: FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION)

TABLE 53 NORTH AMERICA: FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2017–2025 (USD MILLION)

TABLE 54 NORTH AMERICA: FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION)

TABLE 55 NATIONAL AVERAGE MEDICARE REIMBURSEMENT: OUTPATIENT PROSPECTIVE PAYMENT SYSTEM (OPPS) ESTIMATED PER COURSE

TABLE 56 NCI FUNDING, BY RESEARCH AREA, 2015–2017 (USD MILLION)

TABLE 57 US: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 58 US: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 59 CANADA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 60 CANADA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 61 EUROPE: FIDUCIAL MARKERS MARKET, BY COUNTRY, 2017–2025
(USD MILLION)

TABLE 62 EUROPE: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025
(USD MILLION)

TABLE 63 EUROPE: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE,
2017–2025 (USD MILLION)

TABLE 64 EUROPE: FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025
(USD MILLION)

TABLE 65 EUROPE: FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2017–2025
(USD MILLION)

TABLE 66 EUROPE: FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025
(USD MILLION)

TABLE 67 GERMANY: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025
(USD MILLION)

TABLE 68 GERMANY: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE,
2017–2025 (USD MILLION)

TABLE 69 UK: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD
MILLION)

TABLE 70 UK: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025
(USD MILLION)

TABLE 71 FRANCE: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025
(USD MILLION)

TABLE 72 FRANCE: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE,
2017–2025 (USD MILLION)

TABLE 73 SPAIN: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD
MILLION)

TABLE 74 SPAIN: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE,
2017–2025 (USD MILLION)

TABLE 75 ITALY: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD
MILLION)

TABLE 76 ITALY: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE,
2017–2025 (USD MILLION)

TABLE 77 ROE: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD
MILLION)

TABLE 78 ROE: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE,
2017–2025 (USD MILLION)

TABLE 79 ASIA PACIFIC: FIDUCIAL MARKERS MARKET, BY COUNTRY, 2017–2025
(USD MILLION)

TABLE 80 ASIA PACIFIC: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025

(USD MILLION)

TABLE 81 ASIA PACIFIC: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 82 ASIA PACIFIC: FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION)

TABLE 83 ASIA PACIFIC: FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2017–2025 (USD MILLION)

TABLE 84 ASIA PACIFIC: FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION)

TABLE 85 JAPAN: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 86 JAPAN: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 87 CHINA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 88 CHINA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 89 INDIA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 90 INDIA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 91 SOUTH KOREA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 92 SOUTH KOREA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 93 AUSTRALIA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 94 AUSTRALIA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 95 ROAPAC: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 96 ROAPAC: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 97 LATIN AMERICA: FIDUCIAL MARKERS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)

TABLE 98 LATIN AMERICA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 99 LATIN AMERICA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 100 LATIN AMERICA: FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION)

TABLE 101 LATIN AMERICA: FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2017–2025 (USD MILLION)

TABLE 102 LATIN AMERICA: FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION)

TABLE 103 BRAZIL: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 104 BRAZIL: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 105 MEXICO: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 106 MEXICO: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 107 ROLA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 108 ROLA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 109 MEA: FIDUCIAL MARKERS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)

TABLE 110 MEA: METAL-BASED FIDUCIAL MARKERS MARKET, BY TYPE, 2017–2025 (USD MILLION)

TABLE 111 MEA: FIDUCIAL MARKERS MARKET, BY MODALITY, 2017–2025 (USD MILLION)

TABLE 112 MEA: FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2017–2025 (USD MILLION)

TABLE 113 MEA: FIDUCIAL MARKERS MARKET, BY END USER, 2017–2025 (USD MILLION)

List Of Figures

LIST OF FIGURES

FIGURE 1 FIDUCIAL MARKERS MARKET: RESEARCH METHODOLOGY STEPS

FIGURE 2 RESEARCH DESIGN

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING

FIGURE 5 FIDUCIAL MARKERS MARKET: PRODUCT-BASED ESTIMATION

FIGURE 6 FIDUCIAL MARKERS MARKET: END USER-BASED ESTIMATION

FIGURE 7 FIDUCIAL MARKERS MARKET: DATA TRIANGULATION

FIGURE 8 FIDUCIAL MARKERS MARKET SHARE, BY PRODUCT, 2019 VS. 2025

FIGURE 9 FIDUCIAL MARKERS MARKET SHARE, BY MODALITY, 2019 VS. 2025

FIGURE 10 FIDUCIAL MARKERS MARKET, BY CANCER TYPE, 2019–2025 (USD MILLION)

FIGURE 11 FIDUCIAL MARKERS MARKET, BY END USER, 2019–2025 (USD MILLION)

FIGURE 12 FIDUCIAL MARKERS MARKET, BY REGION: GEOGRAPHICAL SNAPSHOT

FIGURE 13 GROWING ADOPTION OF IMAGE-GUIDED RADIOTHERAPY ACROSS THE GLOBE IS SUPPORTING THE GROWTH OF THE MARKET

FIGURE 14 METAL-BASED MARKERS COMMAND THE LARGEST MARKET SHARE

FIGURE 15 CT/CBCT SEGMENT DOMINATES THE GLOBAL MARKET DURING THE FORECAST PERIOD

FIGURE 16 PROSTATE CANCER SEGMENT WILL HOLD THE MAJOR SHARE OF THE MARKET DURING THE FORECAST PERIOD

FIGURE 17 HOSPITALS & OUTPATIENT FACILITIES SEGMENT COMMAND THE LARGEST MARKET SHARE

FIGURE 18 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD

FIGURE 19 FIDUCIAL MARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 20 NUMBER OF NEW CANCER CASES DIAGNOSED, BY COUNTRY, 2018 (THOUSAND)

FIGURE 21 NORTH AMERICA: FIDUCIAL MARKERS MARKET SNAPSHOT

FIGURE 22 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2016 TO 2019

FIGURE 23 CIVCO RADIOTHERAPY HELD THE LEADING POSITION IN THE

FIDUCIAL MARKERS MARKET, 2018

FIGURE 24 FIDUCIAL MARKERS MARKET (GLOBAL) COMPETITIVE LEADERSHIP
MAPPING, 2019

FIGURE 25 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT

FIGURE 26 IBA: COMPANY SNAPSHOT

FIGURE 27 MEDTRONIC: COMPANY SNAPSHOT

FIGURE 28 ECKERT & ZIEGLER: COMPANY SNAPSHOT

I would like to order

Product name: Fiducial Markers Market by Product (Metal Based Markers (Gold, Gold Combination) Polymer Markers), Cancer Type (Prostate, Lung, Breast), Modality (CT, CBCT, MRI, Ultrasound), End user (Hospitals, Outpatient Facilities) - Global Forecast to 2025

Product link: <https://marketpublishers.com/r/F4E7A6A56F8AEN.html>

Price: US\$ 5,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F4E7A6A56F8AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970